Insufficient scRNA-seq data for expression of KLHL25 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 1126.56 | 1445 / 1445 | 100% | 9.93 | 183 / 183 |
stomach | 100% | 864.77 | 359 / 359 | 99% | 8.50 | 284 / 286 |
prostate | 100% | 1049.95 | 245 / 245 | 99% | 6.39 | 498 / 502 |
intestine | 100% | 764.99 | 966 / 966 | 99% | 8.59 | 522 / 527 |
brain | 99% | 789.91 | 2613 / 2642 | 100% | 29.74 | 705 / 705 |
uterus | 100% | 1147.65 | 170 / 170 | 98% | 8.49 | 452 / 459 |
breast | 100% | 1142.04 | 458 / 459 | 98% | 6.93 | 1097 / 1118 |
bladder | 100% | 755.33 | 21 / 21 | 96% | 6.06 | 482 / 504 |
liver | 100% | 1881.24 | 225 / 226 | 95% | 5.79 | 385 / 406 |
skin | 100% | 1294.73 | 1809 / 1809 | 94% | 4.30 | 444 / 472 |
lung | 99% | 950.17 | 575 / 578 | 94% | 5.69 | 1083 / 1155 |
thymus | 99% | 602.66 | 648 / 653 | 92% | 4.17 | 558 / 605 |
ovary | 100% | 667.41 | 180 / 180 | 91% | 5.72 | 391 / 430 |
adrenal gland | 98% | 491.73 | 254 / 258 | 72% | 2.92 | 165 / 230 |
kidney | 100% | 733.92 | 89 / 89 | 68% | 2.71 | 613 / 901 |
pancreas | 52% | 149.04 | 170 / 328 | 98% | 9.42 | 174 / 178 |
adipose | 100% | 1315.01 | 1204 / 1204 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 5.42 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 3.86 | 1 / 1 |
blood vessel | 100% | 784.11 | 1329 / 1335 | 0% | 0 | 0 / 0 |
muscle | 98% | 699.32 | 790 / 803 | 0% | 0 | 0 / 0 |
spleen | 97% | 358.38 | 234 / 241 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 93% | 3.40 | 27 / 29 |
heart | 92% | 507.28 | 794 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 65% | 1.95 | 52 / 80 |
peripheral blood | 49% | 213.68 | 458 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0006511 | Biological process | ubiquitin-dependent protein catabolic process |
GO_0016567 | Biological process | protein ubiquitination |
GO_0032831 | Biological process | positive regulation of CD4-positive, CD25-positive, alpha-beta regulatory T cell differentiation |
GO_0006446 | Biological process | regulation of translational initiation |
GO_0046321 | Biological process | positive regulation of fatty acid oxidation |
GO_0045717 | Biological process | negative regulation of fatty acid biosynthetic process |
GO_0005829 | Cellular component | cytosol |
GO_0031463 | Cellular component | Cul3-RING ubiquitin ligase complex |
GO_0005737 | Cellular component | cytoplasm |
GO_1990756 | Molecular function | ubiquitin-like ligase-substrate adaptor activity |
Gene name | KLHL25 |
Protein name | Kelch-like protein 25 (Ectoderm-neural cortex protein 2) (ENC-2) |
Synonyms | ENC2 |
Description | FUNCTION: Substrate-specific adapter of a BCR (BTB-CUL3-RBX1) E3 ubiquitin ligase complex involved in various processes, such as translation homeostasis and lipid synthesis . The BCR(KLHL25) ubiquitin ligase complex acts by mediating ubiquitination of hypophosphorylated EIF4EBP1 (4E-BP1): ubiquitination and subsequent degradation of hypophosphorylated EIF4EBP1 (4E-BP1) probably serves as a homeostatic mechanism to maintain translation and prevent eIF4E inhibition when eIF4E levels are low . The BCR(KLHL25) complex does not target EIF4EBP1 (4E-BP1) when it is hyperphosphorylated or associated with eIF4E . The BCR(KLHL25) complex also acts as a regulator of lipid synthesis by mediating ubiquitination and degradation of ACLY, thereby inhibiting lipid synthesis . BCR(KLHL25)-mediated degradation of ACLY promotes fatty acid oxidation and is required for differentiation of inducible regulatory T (iTreg) cells . . |
Accessions | Q9H0H3 ENST00000337975.6 |